Glioblastoma multiforme Clinical Trials

A listing of Glioblastoma multiforme medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 48 clinical trials
INCMGA00012 and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

In this study, the investigators propose to combine INCMGA00012 with radiation therapy (RT) and bevacizumab with or without epacadostat in the treatment of recurrent glioblastoma (GBM). The

immunotherapeutic agent
measurable disease
glioblastoma multiforme
karnofsky performance status
neutrophil count
  • 0 views
  • 19 Sep, 2021
  • 4 locations
Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

Increasing preclinical and clinical data have shown that myeloid-derived suppressor cells (MDSCs) may represent a significant driver of immunosuppression in glioblastoma (GBM, grade IV

cancer
astrocytoma
temozolomide
neutrophil count
karnofsky performance status
  • 0 views
  • 15 Sep, 2021
  • 1 location
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Background Glioblastoma is a type of brain cancer. Treatments include radiation, chemotherapy, and surgery. But survival rates are poor. Researchers think that the

platelet count
cancer
glioblastoma multiforme
neutrophil count
ct scan
  • 43 views
  • 12 Sep, 2021
  • 1 location
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Background Glioblastoma (GBM) is a type of malignant glioma. These cancers are nearly always fatal. People who develop these cancers get aggressive treatments. But

platelet count
malignant glioma
neutrophil count
beam radiation
gross total resection
  • 0 views
  • 19 Sep, 2021
  • 1 location
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

This phase I trial studies the side effects and best dose of MDM2 inhibitor KRT-232 in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent

neutrophil count
karnofsky performance status
hydroxychloroquine
bilateral tubal ligation
malignant brain tumor
  • 127 views
  • 16 Sep, 2021
  • 3 locations
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioblastoma With Elevated Mutational Burden

This phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioblastoma that has come back (recurrent) and carries a high number of

  • 0 views
  • 19 Sep, 2021
  • 312 locations
Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma Phase III

The aim of this Phase III study is to evaluate the superiority of dose-dense temozolomide (ddTMZ) followed by bevacizumab at ddTMZ failure for glioblastoma at first recurrence or progression

measurable disease
neutron capture therapy
karnofsky performance status
bevacizumab
temozolomide
  • 539 views
  • 10 Sep, 2021
  • 37 locations
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress v 3 and v 5 Integrins.

(r/r) glioblastoma multiforme (GBM) or Human Epidermal growth factor Receptor 2 positive (Her2+) breast cancer that has metastasized to the brain expected to overexpress alpha-v beta 3 (v3) and alpha

EGFR
cancer
HER2
bevacizumab
  • 0 views
  • 16 Sep, 2021
  • 1 location
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

This pilot phase II trial studies how well ferumoxytol magnetic resonance imaging (MRI) works in assessing response to pembrolizumab in patients with glioblastoma. Diagnostic procedures, such as

anticoagulant therapy
pembrolizumab
dexamethasone
neutrophil count
aptt
  • 44 views
  • 19 Sep, 2021
  • 1 location
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

Background Gliomas are the most common malignant brain tumors. Some have certain changes (mutations) in the genes IDH1 or IDH2. If there are a high number of mutations in a tumor, it is called hypermutator phenotype (HMP). The drug nivolumab helps the immune system fight cancer. Researchers think it can …

platelet count
cancer
IDH2
brain tumor
nivolumab
  • 38 views
  • 12 Sep, 2021
  • 1 location